Regorafenib for Gastrointestinal Malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Regorafenib for Gastrointestinal Malignancies

Published:2013-02-23 Issue:3 Volume:27 Page:213-224
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Aprile Giuseppe,Macerelli Marianna,Giuliani Francesco

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-013-0014-9.pdf

Reference65 articles.

1. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol. 2003;21:255–61.

2. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–65.

3. Hunter T. Signaling: 2000 and beyond. Cell. 2000;100:113–27.

4. Cohen P. Protein kinases: the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1:309–15.

5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl b-lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers;Bioorganic Chemistry;2023-12

2. Antitumor Therapy Targeting the Tumor Microenvironment;Journal of Oncology;2023-03-03

3. Comparing immunotherapies to other frequently used treatments of gastric cancer;Expert Review of Clinical Pharmacology;2021-07-27

4. Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications;Biomedical Reports;2020-05-12

5. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib;European Journal of Cancer;2020-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3